Nearly a decade ago, venture capitalist Bob Nelsen pitched industry veteran Vicki Sato on launching a company dedicated to tackling pathogens. Sato initially thought it was a crazy idea, as biotech companies had been moving away from infectious disease research. Despite being retired, Sato loved the clarity of chasing pathogens and had experience in HIV and hepatitis C drugs. The idea was financially risky, but Nelsen had a history of success with unconventional ideas in science. This partnership marked a shift towards focusing on infectious diseases, a departure from the trend in the biotech industry.
Source link
Can investing in infectious disease pay off? Vir shows its a struggle
